Lakefront Biotherapeutics NV clinical trials

Also known as Galapagos, GLPG.

The registry lists 116 studies whose lead sponsor is Lakefront Biotherapeutics NV or one of 1 company grouped under it. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 116. Browse all 116 →

• Long-Term Follow-Up Study of GamgertamigNot yet recruitingNCT07847892

  Sponsor listed in the registry: Lakefront Biotherapeutics West LLC

• OM336 in Autoimmune CytopeniasRecruitingNCT07083960Phase 1

  Sponsor listed in the registry: Lakefront Biotherapeutics West LLC

• Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell TherapiesRecruitingNCT06652633Phase 3
• OM336 in Seropositive Autoimmune DiseasesRecruitingNCT07229144Phase 1

  Sponsor listed in the registry: Lakefront Biotherapeutics West LLC

• A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaTerminatedNCT06561425Phase 1/2
• A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusCompletedNCT05856448Phase 2
• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisCompletedNCT05695950Phase 2
• Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseTerminatedNCT03201445Phase 2
• A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionTerminatedNCT05479058Phase 3

  Sponsor listed in the registry: Galapagos NV

• A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970CompletedNCT04106297Phase 1
• Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy SubjectsCompletedNCT04971746Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667CompletedNCT04097938Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult SubjectsCompletedNCT04856358Phase 1

  Sponsor listed in the registry: Galapagos NV

• Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy SubjectsCompletedNCT05272683Phase 1

  Sponsor listed in the registry: Galapagos NV

• Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy SubjectsCompletedNCT04720183Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)TerminatedNCT04578548Phase 2

  Sponsor listed in the registry: Galapagos NV

• Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseTerminatedNCT02914600Phase 3

  Sponsor listed in the registry: Galapagos NV

• Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsCompletedNCT02065700Phase 2

  Sponsor listed in the registry: Galapagos NV

• Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisCompletedNCT03926195Phase 2

  Sponsor listed in the registry: Galapagos NV

• First-in-Human Single Ascending Dose of GLPG0492CompletedNCT01130818Phase 1

  Sponsor listed in the registry: Galapagos NV

• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseCompletedNCT02914561Phase 3
• Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy SubjectsCompletedNCT06043739Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)TerminatedNCT04700280Phase 2

  Sponsor listed in the registry: Galapagos NV

• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative ColitisCompletedNCT04577794Phase 2

  Sponsor listed in the registry: Galapagos NV

• A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareTerminatedNCT03733444Phase 3

  Sponsor listed in the registry: Galapagos NV

• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareTerminatedNCT03711162Phase 3

  Sponsor listed in the registry: Galapagos NV

• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to MethotrexateCompletedNCT04577781Phase 2

  Sponsor listed in the registry: Galapagos NV

• Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667CompletedNCT05335447Phase 1
• An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.TerminatedNCT03320876Phase 2

  Sponsor listed in the registry: Galapagos NV

• A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic SclerosisTerminatedNCT03976648Phase 2

  Sponsor listed in the registry: Galapagos NV

• A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsCompletedNCT04976270Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult SubjectsCompletedNCT04653467Phase 1

  Sponsor listed in the registry: Galapagos NV

• Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy SubjectsCompletedNCT05030857Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus ErythematosusTerminatedNCT04700267Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT03725852Phase 2

  Sponsor listed in the registry: Galapagos NV

• A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee OsteoarthritisCompletedNCT03595618Phase 2

  Sponsor listed in the registry: Galapagos NV

• Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970CompletedNCT04907149Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque PsoriasisCompletedNCT04594928Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059TerminatedNCT04575818Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic SclerosisCompletedNCT03798366Phase 2

  Sponsor listed in the registry: Galapagos NV

• Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205CompletedNCT04704739Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970CompletedNCT04708184Phase 1

  Sponsor listed in the registry: Galapagos NV

• Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy SubjectsCompletedNCT04736927Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic DermatitisTerminatedNCT03864627Phase 2

  Sponsor listed in the registry: Galapagos NV

• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male SubjectsCompletedNCT04532567Phase 1

  Sponsor listed in the registry: Galapagos NV

• Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)CompletedNCT01894516Phase 2

  Sponsor listed in the registry: Galapagos NV

• Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)CompletedNCT01888874Phase 2

  Sponsor listed in the registry: Galapagos NV

• Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02738801Phase 2

  Sponsor listed in the registry: Galapagos NV

• A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory DiseasesCompletedNCT03800472Phase 1

  Sponsor listed in the registry: Galapagos NV

• A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic DermatitisTerminatedNCT03689829Phase 1

  Sponsor listed in the registry: Galapagos NV